Correlation Between Larimar Therapeutics and Milestone Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Larimar Therapeutics and Milestone Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Larimar Therapeutics and Milestone Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Larimar Therapeutics and Milestone Pharmaceuticals, you can compare the effects of market volatilities on Larimar Therapeutics and Milestone Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Larimar Therapeutics with a short position of Milestone Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Larimar Therapeutics and Milestone Pharmaceuticals.

Diversification Opportunities for Larimar Therapeutics and Milestone Pharmaceuticals

-0.03
  Correlation Coefficient

Good diversification

The 3 months correlation between Larimar and Milestone is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Larimar Therapeutics and Milestone Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Milestone Pharmaceuticals and Larimar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Larimar Therapeutics are associated (or correlated) with Milestone Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Milestone Pharmaceuticals has no effect on the direction of Larimar Therapeutics i.e., Larimar Therapeutics and Milestone Pharmaceuticals go up and down completely randomly.

Pair Corralation between Larimar Therapeutics and Milestone Pharmaceuticals

Given the investment horizon of 90 days Larimar Therapeutics is expected to generate 70.33 times less return on investment than Milestone Pharmaceuticals. In addition to that, Larimar Therapeutics is 1.84 times more volatile than Milestone Pharmaceuticals. It trades about 0.0 of its total potential returns per unit of risk. Milestone Pharmaceuticals is currently generating about 0.2 per unit of volatility. If you would invest  139.00  in Milestone Pharmaceuticals on September 3, 2024 and sell it today you would earn a total of  60.00  from holding Milestone Pharmaceuticals or generate 43.17% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Larimar Therapeutics  vs.  Milestone Pharmaceuticals

 Performance 
       Timeline  
Larimar Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Larimar Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable primary indicators, Larimar Therapeutics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.
Milestone Pharmaceuticals 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Larimar Therapeutics and Milestone Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Larimar Therapeutics and Milestone Pharmaceuticals

The main advantage of trading using opposite Larimar Therapeutics and Milestone Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Larimar Therapeutics position performs unexpectedly, Milestone Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Milestone Pharmaceuticals will offset losses from the drop in Milestone Pharmaceuticals' long position.
The idea behind Larimar Therapeutics and Milestone Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance